非酒精性脂肪性肝病发生及进展的危险因素

姚诚子; 冯巩; 宇文思; 杜欢; 弥曼

doi:10.3969/j.issn.1001-5256.2020.02.044

非酒精性脂肪性肝病发生及进展的危险因素

DOI: 10.3969/j.issn.1001-5256.2020.02.044

1. 西安医学院
2. 兴平市人民医院内科

基金项目:

陕西省普通高等学校优势学科建设项目(陕教位[2014]3号)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 904
- HTML全文浏览量: 34
- PDF下载量: 238
- 被引次数: 0
出版历程
- 收稿日期: 2019-08-16
- 出版日期: 2020-02-20

Risk factors for the development and progression of nonalcoholic fatty liver disease

Xi'an Medical University

Research funding:

摘要

摘要:
非酒精性脂肪性肝病(NAFLD)的患病率逐年增加,目前成为我国成年人中最常见的慢性肝病之一。NAFLD可由非酒精性肝脂肪变性进展为非酒精性脂肪性肝炎、肝硬化、肝细胞癌及NAFLD相关性心血管事件、死亡等重大疾病。现对NAFLD发生的危险因素以及进展为肝纤维化、肝硬化、肝癌、相关心血管事件和死亡等重大疾病的相关危险因素进行综述,以便进一步探讨NAFLD发生发展的机制,降低NAFLD的患病率,减缓NAFLD的进展程度,降低相关疾病的病死率。
- 非酒精性脂肪性肝病 /
- 危险因素
Abstract:
The prevalence rate of nonalcoholic fatty liver disease( NAFLD) is increasing year by year,and at present,it has become one of the most common chronic liver diseases in adults in China. NAFLD can progress from nonalcoholic fatty degeneration of the liver to nonalcoholic steatohepatitis,liver cirrhosis,hepatocellular carcinoma,NAFLD-associated cardiovascular events,and death. This article reviews the risk factors for the development of NAFLD and the progression of NAFLD to major diseases such as liver fibrosis,liver cirrhosis,liver cancer,related cardiovascular events,and death,in order to further explore the mechanism of the development and progression of NAFLD,reduce the prevalence rate of NAFLD,slow down the progression of NAFLD,reduce the mortality rate of related diseases,and achieve better prevention and treatment.
- non-alcoholic fatty liver disease /
- risk factors

HTML全文

参考文献(37)

[1] SWEET PH,KHOO T,NGUYEN S. Nonalcoholic fatty liver disease[J]. Prim Care,2017,44(4):599-607.

[2] YOUNOSSI ZM,KOENIG AB,ABDELATIF D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J].Hepatology,2016,64(1):73-84.

[3] YOUNOSSI Z,ANSTEE QM,MARIETTI M,et al. Global burden of NAFLD and NASH:Trends,predictions,risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol,2018,15(1):11-20.

[4] YOUNOSSI ZM. Non-alcoholic fatty liver disease-A global public health perspective[J]. J Hepatol,2019,70(3):531-544.

[5] PALMER ND,MUSANI SK,YERGES-ARMSTRONG LM,et al. Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent[J]. Hepatology,2013,58(3):966-975.

[6] SZANTO KB,LI J,CORDERO P,et al. Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease[J]. Diabetes Metab Syndr Obes,2019,12:357-367.

[7] KALIA HS,GAGLIO PJ. The prevalence and pathobiology of nonalcoholic fatty liver disease in patients of different races or ethnicities[J]. Clin Liver Dis,2016,20(2):215-224.

[8] HU XY,LI Y,LI LQ,et al. Risk factors and biomarkers of non-alcoholic fatty liver disease:An observational cross-sectional population survey[J]. BMJ Open, 2018, 8(4):e019974.

[9] YOUNOSSI Z,TACKE F,ARRESE M,et al. Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. Hepatology,2019,69(6):2672-2682.

[10] FARZANEGI P,DANA A,EBRAHIMPOOR Z,et al. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease(NAFLD):Roles of oxidative stress and inflammation[J]. Eur J Sport Sci,2019,19(7):994-1003.

[11] KATO A,LI Y,OTA A,et al. Smoking results in accumulation of ectopic fat in the liver[J]. Diabetes Metab Syndr Obes,2019,12:1075-1080.

[12] TER HORST KW,SERLIE MJ. Fructose consumption,lipogenesis,and non-alcoholic fatty liver disease[J]. Nutrients,2017,9(9):e981.

[13] CHAKRABORTY A,CHOUDHURY A,SAHA A. Development of non-alcoholic fatty liver disease(NAFLD)in young obese tribal subjects of Tripura:Link between low 25(OH)vitamin-D levels and immune modulators[J]. J Assoc Physicians India,2019,67(8):52-56.

[14] KOPLAY M,GULCAN E,OZKAN F. Association between serum vitamin B12 levels and the degree of steatosis in patients with nonalcoholic fatty liver disease[J]. J Investig Med,2011,59(7):1137-1140.

[15] PAN X,CHEN B,LIU W,et al. Circulating iron levels interaction with central obesity on the risk of nonalcoholic fatty liver disease:A case-control study in southeast China[J]. Ann Nutr Metab,2019,74(3):207-214.

[16] AIGNER E,WEISS G,DATZ C. Dysregulation of iron and copper homeostasis in nonalcoholic fatty liver[J]. World J Hepatol,2015,7(2):177-188.

[17] LEE SH,KIM MJ,KIM YS,et al. Low hair copper concentration is related to a high risk of nonalcoholic fatty liver disease in adults[J]. J Trace Elem Med Biol,2018,50:28-33.

[18] NCD Risk Factor Collaboration(NCD-Ris C). Trends in adult body-mass index in 200 countries from 1975 to 2014:A pooled analysis of 1698 population-based measurement studies with 19. 2 million participants[J]. Lancet,2016,387(10026):1377-1396.

[19] ARGO CK,HENRY ZH. Editoria:l “Lean”NAFLD:Metabolic obesity with normal BMI…Is it in the genes?[J]. Am J Gastroenterol,2017,112(1):111-113.

[20] FAN JG,KIM SU,WONG VW. New trends on obesity and NAFLD in Asia[J]. J Hepatol,2017,67(4):862-873.

[21] SHAO C,YE J,LI F,et al. Different predictors of steatosis and fibrosis severity among lean,overweight and obese patients with nonalcoholic fatty liver disease[J]. Dig Liver Dis,2019,51(10):1392-1399.

[22] YANG H,LI D,SONG X,et al. Joint associations of serum uric acid and ALT with NAFLD in elderly men and women:A Chinese cross-sectional study[J]. J Transl Med,2018,16(1):285.

[23] ZHOU Y,WEI F,FAN Y. High serum uric acid and risk of nonalcoholic fatty liver disease:A systematic review and metaanalysis[J]. Clin Biochem,2016,49(7-8):636-642.

[24] BRUNO ADE S,RODRIGUES MH,ALVARES MC,et al. Non-alcoholic fatty liver disease and its associated risk factors in Brazilian postmenopausal women[J]. Climacteric,2014,17(4):465-471.

[25] LI B,ZHANG C,ZHAN YT. Nonalcoholic fatty liver disease cirrhosis:A review of its epidemiology,risk factors,clinical presentation,diagnosis,management,and prognosis[J].Can J Gastroenterol Hepatol,2018,2018:2784537.

[26] NOUREDDIN M,YATES KP,VAUGHN IA,et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients[J]. Hepatology,2013,58(5):1644-1654.

[27] ALKHOURI N,POORDAD F,LAWITZ E. Management of nonalcoholic fatty liver disease:Lessons learned from type 2 diabetes[J]. Hepatol Commun,2018,2(7):778-785.

[28] POREPA L,RAY JG,SANCHEZ-ROMEU P,et al. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease[J]. CMAJ,2010,182(11):e526-e531.

[29] MARENGO A,JOUNESS RI,BUGIANESI E. Progression and natural history of nonalcoholic fatty liver disease in adults[J].Clin Liver Dis,2016,20(2):313-324.

[30] SAID A,GHUFRAN A. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma[J]. World J Clin Oncol,2017,8(6):429-436.

[31] LEE S,ZHANG C,LIU Z,et al. Network analyses identify liver-specific targets for treating liver diseases[J]. Mol Syst Biol,2017,13(8):938.

[32] DALAMAGA M,DIAKOPOULOS KN,MANTZOROS CS. The role of adiponectin in cancer:A review of current evidence[J]. Endocr Rev,2012,33(4):547-594.

[33] ZOLLER H,TILG H. Nonalcoholic fatty liver disease and hepatocellular carcinoma[J]. Metabolism,2016,65(8):1151-1160.

[34] SORRENTINO P,D’ANGELO S,FERBO U,et al. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis[J]. J Hepatol,2009,50(2):351-357.

[35] HASSAN MM,ABDEL-WAHAB R,KASEB A,et al. Obesity early in adulthood increases risk but does not affect outcomes of hepatocellular carcinoma[J]. Gastroenterology,2015,149(1):119-129.

[36] TOMITA K,TERATANI T,SUZUKI T,et al. Free cholesterol accumulation in hepatic stellate cells:Mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice[J].Hepatology,2014,59(1):154-169.

[37] SAFIRI S,KHAZAEI S,MANSORI K,et al. Comments on“Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease:Systematic review and meta-analysis”[J].Hepatology,2017,66(4):1358-1359.

施引文献

资源附件(0)

访问统计